IRB 101 for Greater than Minimal Risk Studies

September 18, 2019 -

12:00pm to 1:30pm


This session will provide new researchers with the basic skills to manage a study that will be submitted for IRB committee review.  Attendees will learn about the role and responsibilities of the IRB, submission and review process, and regulatory issues commonly encountered with greater than minimal risk studies. This session will focus on the full board review process and include an introduction on the use of FDA regulated drugs and devices in research.

This session is relevant for coordinators, postdocs, graduate students and faculty members who will be involved with human subject research including, but not limited to drugs, medical devices, and other procedures that may expose participants to more than minimal risk. This session and the IRB 101 for Expedited Studies contain similar introductory information.  This session will be repeated on November 7, 2019

Click here to register for the program.  Submit advance questions or comments to


Melissa Miklos, MSL, CIP - HRPO Associate Director

Location and Address

Hieber Building
3500 Fifth Avenue
Learning Resource Center
Room 305